SCHEMBL770840

SCHEMBL770840

CCOC(=O)CN(CCc1ccc(Cl)cc1)C(=O)CCCC(=O)N1CCCC2CCCC=C21

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C19 P33261 1/20 0.37
POLB P06746 1/20 0.37
NAAA Q02083 1/20 0.36
C5AR1 P21730 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
F10 P00742 1/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
FKBP1A P62942 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770024 0.93 HRH3 (0.35) ALDH1A1CYP3A4CYP2C19NAAAHRH3
SCHEMBL770267 0.92 ALOX5 (0.38) ALDH1A1CYP1A2CYP3A4MAPTCYP2C19
SCHEMBL770669 0.90 KCNH2 (0.38) ALDH1A1MAPTPOLBHRH3KMT2A
SCHEMBL770279 0.88 ALDH1A1 (0.41) ALDH1A1CYP3A4MAPTCYP2C19POLB
SCHEMBL772068 0.81 SMN1; SMN2 (0.46) ALDH1A1CYP1A2CYP3A4MAPTCYP2C19
SCHEMBL770839 0.80 DRD2 (0.47) ALDH1A1CYP1A2CYP3A4MAPTCYP2C19
SCHEMBL772447 0.80 ALDH1A1 (0.41) ALDH1A1CYP3A4CYP2C19NPC1RAB9A
SCHEMBL770041 0.79 RAB9A (0.42) ALDH1A1CYP1A2CYP3A4MAPTCYP2C19
SCHEMBL771753 0.79 KMT2A (0.44) ALDH1A1CYP1A2KMT2ANPC1SMN1; SMN2
SCHEMBL771071 0.78 TPSAB1 (0.38) ALDH1A1SMN1; SMN2F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 144/4885CYP1A2 167/4885CYP3A4 319/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 142/4885CYP1A2 167/4885CYP3A4 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.